URL has been copied successfully!
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Yesterday was a brutal day for biotech stocks, but one company withstood the broad selloff. We also look at investor excitement for longevity startups and yet another licensing deal made by Eli Lilly.
Legend Biotech emerged as a rare market winner
Shares of Legend Biotech soared over 40% yesterday after the company disclosed early data on its in vivo CAR-T therapy that showed promise in Non-Hodgkin’s lymphoma.
Please follow us:
